Skip to content

Study · Case report or series · n = 3 · 2023

4 results

Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.

Yammine L, Balderas JC, Weaver MF, Schmitz JM

Journal of addiction medicine17 Feb 2023Cited by 20 (Europe PMC)

PMID37579116 (opens in a new tab)DOI10.1097/adm.0000000000001147 (opens in a new tab)PepBankPUB-37579116
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesOther

    In 3 patients with cocaine use disorder receiving exenatide and standard counseling, attendance and compliance were excellent.

    In plain wordsIn 3 patients with cocaine use disorder who received exenatide and standard counseling, attendance and treatment compliance were excellent.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAttendance and compliance
    Study

    n = 3

    Outcome group
    Treatment adherence and retention · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    We observed excellent attendance and compliance, along with positive end-of-study satisfaction ratings.
    1 context sentence
    Summary · context
    Here, we assess feasibility and safety by reporting on 3 cases of patients with CUD who received 6 weeks of exenatide 2 mg subcutaneously once-weekly in an open-label fashion, along with standard individual drug counseling.
  2. 02HumanCase report or seriesOther

    In patients with cocaine use disorder receiving exenatide and standard counseling, end-of-study satisfaction ratings were positive.

    In plain wordsIn patients with cocaine use disorder who received exenatide and standard counseling, final satisfaction ratings were positive.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEnd-of-study satisfaction
    Study

    n = 3

    Outcome group
    Treatment adherence and retention · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    We observed excellent attendance and compliance, along with positive end-of-study satisfaction ratings.
    1 context sentence
    Summary · context
    Here, we assess feasibility and safety by reporting on 3 cases of patients with CUD who received 6 weeks of exenatide 2 mg subcutaneously once-weekly in an open-label fashion, along with standard individual drug counseling.
  3. 03HumanCase report or seriesSafety outcome

    In 3 patients with cocaine use disorder, exenatide was well tolerated and without unexpected or severe adverse events.

    In plain wordsIn 3 patients with cocaine use disorder, exenatide was well tolerated, with no unexpected or severe adverse events.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTolerability and unexpected or severe adverse events
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    The medication was well tolerated and without unexpected or severe adverse events.
    1 context sentence
    Summary · context
    Here, we assess feasibility and safety by reporting on 3 cases of patients with CUD who received 6 weeks of exenatide 2 mg subcutaneously once-weekly in an open-label fashion, along with standard individual drug counseling.
  4. 04HumanCase report or seriesEfficacy outcome

    In patients with cocaine use disorder receiving exenatide and standard counseling, cocaine use and related clinical results were mixed.

    In plain wordsIn patients with cocaine use disorder who received exenatide and standard counseling, cocaine use and related clinical results were mixed.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedCocaine use and related clinical effects
    Study

    n = 3

    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Results for cocaine use and related clinical effects were more mixed, yet encouraging.
    1 context sentence
    Summary · context
    Here, we assess feasibility and safety by reporting on 3 cases of patients with CUD who received 6 weeks of exenatide 2 mg subcutaneously once-weekly in an open-label fashion, along with standard individual drug counseling.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2Results postedNCT04941521

Exenatide for Treating Cocaine Use Disorder

The University of Texas Health Science Center, Houstonn = 324 Jun 2021 to 17 Nov 2021

Cocaine Use Disorder

Trial pageClinicalTrials.govUpdated 27 Jun 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.